Skip to main content
Article
Are there mortality risks for patients with epilepsy who use cannabis treatments as monotherapy?
Epilepsy Behav Case Rep
  • Devon M Kollmyer, Swedish Epilepsy Center, 550 17th Ave suite 540, Seattle, WA 98122, USA
  • Kyla E Wright
  • Nicole M Warner, Swedish Epilepsy Center, 550 17th Ave suite 540, Seattle, WA 98122, USA
  • Michael J Doherty, Swedish Epilepsy Center, 550 17th Ave suite 540, Seattle, WA 98122, USA
Document Type
Article
Publication Date
1-1-2019
Keywords
  • Cannabidiol,
  • Marijuana,
  • Sudden unexplained death in epilepsy,
  • Tetrahydrocannabinol,
  • Therapy
Disciplines
Abstract

Mortality associated with cannabis used for treatment of epilepsy is not well documented. We discuss two fatalities in the setting of epilepsy and self-determined therapy with cannabis (SDTC). One patient had probable sudden unexpected death in epilepsy, the second death was due to seizure-associated drowning. Both directed SDTC over conventional anti-seizure medications. Where recreational cannabis is legal, decisions to use cannabis are often self-directed and independent of physician advice of cannabis risks, in part because physicians may not be aware of the risk of SDTC. Further study of morbidity and mortality of SDTC in patients with epilepsy is needed.

Clinical Institute
Neurosciences (Brain & Spine)
Specialty
Neurosciences
Citation Information
Devon M Kollmyer, Kyla E Wright, Nicole M Warner and Michael J Doherty. "Are there mortality risks for patients with epilepsy who use cannabis treatments as monotherapy?" Epilepsy Behav Case Rep (2019)
Available at: http://works.bepress.com/michael-doherty/2/